Does CARFILZOMIB Cause Second primary malignancy? 29 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 29 reports of Second primary malignancy have been filed in association with CARFILZOMIB (KYPROLIS). This represents 0.1% of all adverse event reports for CARFILZOMIB.
29
Reports of Second primary malignancy with CARFILZOMIB
0.1%
of all CARFILZOMIB reports
14
Deaths
7
Hospitalizations
How Dangerous Is Second primary malignancy From CARFILZOMIB?
Of the 29 reports, 14 (48.3%) resulted in death, 7 (24.1%) required hospitalization, and 4 (13.8%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CARFILZOMIB. However, 29 reports have been filed with the FAERS database.
What Other Side Effects Does CARFILZOMIB Cause?
Plasma cell myeloma (2,238)
Off label use (2,120)
Death (1,442)
Thrombocytopenia (1,265)
Fatigue (1,048)
Pneumonia (1,016)
Pyrexia (969)
Anaemia (910)
Dyspnoea (881)
Neutropenia (874)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which CARFILZOMIB Alternatives Have Lower Second primary malignancy Risk?
CARFILZOMIB vs CARGLUMIC ACID
CARFILZOMIB vs CARIPRAZINE
CARFILZOMIB vs CARISOPRODOL
CARFILZOMIB vs CARMUSTINE
CARFILZOMIB vs CARTEOLOL